ViewRay Falls on Preliminary Q1 Numbers; Outlook Disappoints
Market News

ViewRay Falls on Preliminary Q1 Numbers; Outlook Disappoints

Shares of radiation therapy systems provider ViewRay (NASDAQ:VRAY) are tanking today after the company announced preliminary first-quarter numbers.

Revenue for the quarter is seen at $23 million compared to $19 million in the year-ago period. In contrast, the net loss is seen widening to $29 million from $26 million a year ago. Analysts expect the company to post a net loss per share of $0.15 for the quarter on May 4. During Q1, ViewRay bagged orders worth $68 million. Further, the total backlog increased to $411 million from $331 million a year ago.

In the current macroeconomic environment, ViewRay expects delayed delivery schedules. Consequently, revenue growth for fiscal 2023 is pegged between flat to 15% (earlier guidance between 25% to 40% growth). Further, adjusted EBITDA loss is estimated between $75 million and $85 million (earlier guidance between a loss of 70 million to $80 million.

Additionally, the company is looking at strategic alternatives and has roped in Goldman Sachs as a financial advisor. The alternatives include a sale, merger, or business combination.

Overall, the Street has a $7 consensus price target of VRAY pointing to a hefty 132.56% potential upside in the stock. That’s after a nearly 31.6% slide in VRAY shares so far in 2023.

Read full Disclosure

Related Articles
TheFlyViewRay announces commencement of Nasdaq delisting proceedings
TheFlyViewRay files voluntary Chapter 11 petitions
TheFlyViewRay price target lowered to $2 from $6.50 at Piper Sandler
Go Ad-Free with Our App